RECEIVED
CENTRAL FAX CENTER
OCT 13 2006

Application No.: 10/688,059
Reply to Office action of July 17, 2006

Amendments to the Claims:
Please add New Claims 2-19.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A composition for the sustained release of a biologically active polypeptide consisting essentially of ~~comprising~~: a biocompatible polylactide-co-glycolide polymer having dispersed therein a biologically active polypeptide, a sugar and glycine.

2. (New) The composition of claim 1, wherein the glucoregulatory peptide is selected from GLP-1, GLP-2, exendin-3, exendin-4 or a combination thereof.

3. (New) The composition of claim 2, wherein the biologically active polypeptide is present from about 0.01% (w/w) to about 50% (w/w) of the total weight of the composition.

4. (New) The sustained release composition of claim 3, wherein the biologically active polypeptide is present in a range from about 0.1% (w/w) to about 30% (w/w) of the total weight of the composition.

5. (New) The composition of claim 4, wherein the polypeptide is present from about 0.1% (w/w) to about 10% (w/w) of the total weight of the sustained release composition.

6. (New) The composition of claim 5, wherein the polypeptide is present from about 0.5% (w/w) to about 5% (w/w) of the total weight of the sustained release composition.

7. (New) The composition of claim 1, wherein the sugar is present from about 0.01% to about 50% w/w of the total weight of the sustained release composition.

Application No.: 10/688,059
Reply to Office action of July 17, 2006

8. (New) The composition of claim 7, wherein the sugar is present from about 0.01% to about 10% w/w of the total weight of the sustained release composition.

9. (New) The composition of claim 8, wherein the sugar is present from about 0.1% to about 5% w/w of the total weight of the sustained release composition.

10. (New) The composition of claim 1, wherein the sugar is selected from a monosaccharide, a disaccharide, a sugar alcohol or a combination thereof.

11. (New) The composition of claim 10, wherein the sugar is selected from sucrose, trehalose, mannitol and combinations thereof.

12. (New) The composition of claim 11, wherein the sugar is a disaccharide.

13. (New) The sustained release composition of claim 12, wherein the disaccharide is sucrose, trehalose or a combination thereof.

14. (New) A composition for the sustained release of biologically active polypeptide consisting essentially of: a biocompatible polymer having dispersed therein exendin-4, sucrose and glycine.

15. (New) The composition of claim 14, wherein the biocompatible polymer is selected from poly(lactides), poly(glycolides), poly(lactide-co-glycolides), poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s and blends and copolymers thereof.

16. (New) The composition of claim 15, wherein the sucrose is present at a concentration from about 0.01% w/w to about 10% w/w of the total weight of the sustained release composition.

17. (New) The composition of claim 15, wherein the exendin-4 is present at a concentration of about 0.1% to about 10% of the total weight of the composition.

18. (New) A method of treating a patient suffering from Type 2 diabetes comprising administering a therapeutically effective amount of a sustained release composition according to claim 1.

19. (New) A method of treating a patient suffering from Type 2 diabetes comprising administering a therapeutically effective amount of a sustained release composition according to claim 14.